Table 8.6i

Immunosuppression Use for Antirejection Treatment from Transplant

to One Year Following Transplantation, 1996 to 2005

Recipients with Kidney-Pancreas Transplants

  Year of Transplant
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Transplants 860 853 972 941 915 891 905 871 881 903
Tx with Antirejection Treatments 564 317 286 261 232 194 191 154 127 117
Antibodies Any in Category 31.4% 46.7% 44.4% 42.1% 41.4% 32.0% 50.8% 57.8% 63.0% 51.3%
ALG 0.2% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Atgam/NRATG/NRATS 8.9% 18.3% 10.1% 6.5% 3.9% 0.5% 2.6% 1.9% 3.1% 2.6%
OKT3 24.8% 34.7% 35.7% 24.5% 22.8% 12.4% 10.5% 9.7% 11.8% 11.1%
Thymoglobulin 0.0% 0.3% 3.1% 16.1% 15.1% 20.6% 34.0% 39.6% 44.1% 39.3%
Zenapax 0.0% 0.3% 1.7% 1.5% 1.7% 1.0% 4.7% 11.7% 7.1% 7.7%
Simulect 0.0% 0.0% 0.0% 0.4% 2.2% 0.5% 1.0% 1.3% 1.6% 0.0%
Campath 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.5% 3.9% 2.4% 0.0%
Corticosteroids Any in Category 55.3% 69.1% 77.6% 80.5% 82.8% 87.1% 76.4% 68.8% 68.5% 70.9%
Steroids 55.3% 69.1% 77.6% 80.5% 82.8% 87.1% 76.4% 68.8% 68.5% 70.9%
Antimetabolites Any in Category 0.2% 0.0% 0.7% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Cytoxan 0.2% 0.0% 0.7% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Methotrexate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%


Source: OPTN/SRTR Data as of May 1, 2007.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.